Home/Filings/4/0001193125-25-307282
4//SEC Filing

Guyer William 4

Accession 0001193125-25-307282

CIK 0001088856other

Filed

Dec 2, 7:00 PM ET

Accepted

Dec 3, 9:19 PM ET

Size

16.9 KB

Accession

0001193125-25-307282

Insider Transaction Report

Form 4
Period: 2025-12-01
Guyer William
Chief Development Officer
Transactions
  • Award

    Common Stock

    2025-12-01$79.78/sh+224$17,871224 total
  • Gift

    Common Stock

    2025-12-027870 total(indirect: By Trust)
  • Other

    Common Stock

    2025-12-02+7871,235 total
  • Exercise/Conversion

    Common Stock

    2025-12-02$21.65/sh+20,000$433,00021,235 total
  • Sale

    Common Stock

    2025-12-02$80.05/sh19,360$1,549,7661,875 total
  • Sale

    Common Stock

    2025-12-02$80.88/sh640$51,7601,235 total
  • Exercise/Conversion

    Stock option (right to buy)

    2025-12-0220,000270,000 total
    Exercise: $21.65Exp: 2031-09-01Common Stock (20,000 underlying)
Footnotes (8)
  • [F1]The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025.
  • [F2]In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  • [F3]Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  • [F4]Represents the shares held by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee.
  • [F5]Transfer of shares without consideration to the Reporting Person.
  • [F6]This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  • [F7]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.78 to $80.68 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  • [F8]Fully exercisable.

Documents

1 file

Issuer

CORCEPT THERAPEUTICS INC

CIK 0001088856

Entity typeother

Related Parties

1
  • filerCIK 0001879013

Filing Metadata

Form type
4
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 9:19 PM ET
Size
16.9 KB